Reflections on the withdrawal of rofecoxib.
Dalby
Anthony J
AJ
D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D013450:Sulfones / Q000009:adverse effects*
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib